Costs of pharmacological treatment in hypertension and type 2 diabetes mellitus
Main Article Content
Keywords
Hypertension, Costs and Cost Analysis, Drug Costs, Type 2 Diabetes Mellitus
Abstract
Abstract
Background: Hypertension and type 2 diabetes mellitus (T2DM) are prevalent chronic diseases that share common risk factors and contribute significantly to the economic burden on healthcare systems. Their impact is more pronounced in low-income countries, where they increase the prevalence of complications and associated healthcare costs.
Objective: To compare the costs of pharmacological treatment of hypertension according to the number of complications between patients with hypertension vs. patients with hypertension/T2DM.
Material and methods: An analytical cross-sectional study was conducted in two family medicine units in the metropolitan area of Mexico’s central region. Subjects with hypertension and those with hypertension and T2DM were included. Hypertension-related complications were identified, and a microcosting analysis of hypertension pharmacological treatment was performed. To compare treatment costs between both groups it was used the Mann-Whitney U test.
Results: The cost of pharmacological treatment for patients with hypertension and T2DM was $30.5 USD higher compared to those with hypertension alone. The most common complications were heart disease, chronic kidney disease, and hypertensive retinopathy, with costs increasing as the number of complications rose. This effect was more stressed in the hypertension and T2DM group.
Conclusions: The pharmacological treatment cost for patients with hypertension and T2DM was higher compared to those with hypertension alone, even in patients without complications.
References
1. Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16(4):223-37. doi: 10.1038/s41581-019-0244-2
2. Zhao J, Gong R, Sui X, et al. Regional, and national burden, trends, and inequality analysis of maternal hypertensive disorders (MHD) from 1990 to 2021, and predictions to 2046. BMC Pregnancy Childbirth. 2025;25(1):680. doi: 10.1186/s12884-025-07777-9
3. Wang W, Wan Q, Wang S, et al. Management Guidelines for Diabetic Patients with Hypertension. J Diabetes. 2025;17(6):e70093. doi: 10.1111/1753-0407.70093
4. Siniawski D, Masson G, Masson W, et al. Residual cardiovascular risk, use of standard care treatments, and achievement of treatment goals in patients with cardiovascular disease. Int J Cardiol Cardiovasc Risk Prev. 2023;18:200198. doi: 10.1016/j.ijcrp.2023.200198
5. Escobedo-de la Peña J, Ramírez-Hernández JA, Fernández-Ramos MT, et al. Body Fat Percentage Rather than Body Mass Index Related to the High Occurrence of Type 2 Diabetes. Arch Med Res. 2020;51(6):564-71. doi: 10.1016/j.arcmed.2020.05.010
6. Hashmi S, Safdar I, Kazmi MH, et al. Rising Mortality Related to Diabetes Mellitus and Hypertension: Trends and Disparities in the United States (1999−2023). Clin Cardiol. 2025;48(4):e70132. doi: 10.1002/clc.70132
7. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. J Am Coll Cardiol. 2018;71(19):e127-248. doi: 10.1016/j.jacc.2017.11.006
8. Javanbakht M, Mashayekhi A, Baradaran HR, et al. Projection of Diabetes Population Size and Associated Economic Burden through 2030 in Iran: Evidence from Micro-Simulation Markov Model and Bayesian Meta-Analysis. PLOS ONE. 2015;10(7):e0132505. doi: 10.1371/journal.pone.0132505
9. GBD 2021 Stroke Risk Factor Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol. 2024(10):973-1003. doi: 10.1016/S1474-4422(24)00369-7
10. Curado DDSP, Gomes DF, Silva TBC, et al. Direct cost of systemic arterial hypertension and its complications in the circulatory system from the perspective of the Brazilian public health system in 2019. PLoS One. 2021;16(6):e0253063. doi: 10.1371/journal.pone.0253063
11. Bower P, Soiland-Reyes C, Bennett C, et al. The effectiveness and cost-effectiveness of the NHS Diabetes Prevention Programme (NHS-DPP): the DIPLOMA long-term multimethod assessment. Health Soc Care Deliv Res. 2025;1-47. doi: 10.3310/MWKJ5102
12. Figueroa-García J, Granados-García V, Roldán-Valadez E, et al. Cost analysis of drug treatment in hypertensive patients at social security health care family medicine units. Salud Pública de México. 2022;64(2):188-95. doi: 10.21149/12972
13. Adane E, Atnafu A, Aschalew AY. The Cost of Illness of Hypertension and Associated Factors at the University of Gondar Comprehensive Specialized Hospital Northwest Ethiopia, 2018. Clin Outcomes Res. 2020;12:133-40. doi: 10.2147/CEOR.S234674
14. Tipo de cambio para solventar obligaciones denominadas en moneda extranjera pagaderas en la República Mexicana. México: Gobierno de México; 22 de diciembre de 2022. Disponible en: https://www.dof.gob.mx/nota_detalle.php?codigo=5675259&fecha=22/12/2022#gsc.tab=0
15. Instituto Mexicano del Seguro Social. ¿Qué compró el IMSS? México: IMSS; 2024. Disponible en: http://compras.imss.gob.mx/?P=imsscompro
16. Roomaney RA, van Wyk B, Cois A, et al. Inequity in the Distribution of Non-Communicable Disease Multimorbidity in Adults in South Africa: An Analysis of Prevalence and Patterns. Int J Public Health. 2022;67:1605072. doi: 10.3389/ijph.2022.1605072
17. Zhang X, Liu J, Shao S, et al. Sex Differences in the Prevalence of and Risk Factors for Abnormal Glucose Regulation in Adults Aged 50 Years or Older with Normal Fasting Plasma Glucose Levels. Front Endocrinol. 2021;11. doi: 10.3389/fendo.2020.531796
18. Farrukh F, Abbasi A, Jawed M, et al. Hypertension in Women: A South-Asian Perspective. Front Cardiovasc Med. 2022;9. doi: 10.3389/fcvm.2022.880374
19. Kifle ZD, Adugna M, Chanie GS, et al. Prevalence and associated factors of hypertension complications among hypertensive patients at University of Gondar Comprehensive Specialized Referral Hospital. Clin Epidemiol Glob Health. 2022;13:100951. doi: 10.1016/j.cegh.2021.100951
20. Cavender MA, Wirka RC. Blood pressure lowering in the prevention of type 2 diabetes. Lancet. 2021;398(10313):1778-9. doi: 10.1016/S0140-6736(21)02340-0
21. Weycker D, Nichols GA, O’Keeffe-Rosetti M, et al. Risk-Factor Clustering and Cardiovascular Disease Risk in Hypertensive Patients. Am J Hypertens. 2007;20(6):599-607. doi: 10.1016/j.amjhyper.2006.10.013
22. Habib SH, Akter S, Parveen S, et al. Clinical and cost-effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes mellitus. Diabetes Metab Syndr Clin Res Rev. 2008;2(3):163-70. doi: 10.1016/j.dsx.2008.04.008
23. Gnugesser E, Chwila C, Brenner S, et al. The economic burden of treating uncomplicated hypertension in Sub-Saharan Africa: a systematic literature review. BMC Public Health. 2022;22(1):1507. doi: 10.1186/s12889-022-13877-4
24. Qin Z, Li C, Qi S, et al. Association of socioeconomic status with hypertension prevalence and control in Nanjing: a cross-sectional study. BMC Public Health. 2022;22(1):423. doi: 10.1186/s12889-022-12799-5
25. Arshad MS, Alqahtani F, Rasool MF. A Systematic Review of the Economic Burden of Diabetes in Eastern Mediterranean Region Countries. Diabetes Metab Syndr Obes Targets Ther. 2024;17:479-87. doi: 10.2147/DMSO.S440282
26. Campos-Nonato I, Oviedo-Solís C, Vargas-Meza J, et al. Prevalencia, tratamiento y control de la hipertensión arterial en adultos mexicanos: resultados de la Ensanut 2022. Salud Publica Mex. 2023;65:s169-80. doi: 10.21149/14779
Article Sidebar
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors retain their copyright and grant the Revista Médica del IMSS the right of first publication. Articles are distributed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which allows sharing as long as the author and the original source are properly credited.